The objectives of this EAG will include:

1. Development of a target product profile (TPP) to define the intended use, target population, and other desired attributes of the vaccine, including safety and efficacy-related characteristics.

2. Identify vaccine candidates which have passed the necessary pre-clinical immunogenicity and safety pre-requisites

3. Identify key limitations in previous HCV vaccines and resolve new ways to address those limitations

4. In collaboration with the Immunogenicity EAG, standardise protocols for immunogenicity evaluation of candidate vaccines in animal models